AIDX
20/20 Biolabs Inc. · NASDAQ
$0.20-0.01 (-3.00%)today
- Market cap
- $2.7M
- Prev close
- $0.2036
52-week rangeAt the low
$0.188$20.52
20/20 Biolabs Inc. (AIDX) is a Precision Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for AIDX, including 2 SEC filings and 2 press releases and news items. The most recent was published Nov 5, 2026.
Price$0.20-0.01 (-3.00%)
04:00 PM04:15 PM
Financial highlights
Full financials- Revenue, FY2025
- $2.05M
- Revenue growth
- +16.7%
- Net income, FY2025
- -$3.74M
- Net margin
- -182.8%
- Cash
- $4.55M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks31-60%
2026-05-242026-11-15
Mix1890d
- SEC Filings11(61%)
- Other7(39%)
Activity · 52 weeks6142 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRREMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026Board of Directors Recommends a Vote FOR Each Proposal, Including a Reverse Stock Split Authorization Intended to Provide Flexibility to Regain Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement Stockholders of Record as of October 20, 2026 Can Vote Online, by Phone or by Fax in Advance of the 10:00 a.m. Eastern Time Live Webcast GAITHERSBURG, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 BioLabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reminded stockholders to vote their shares ahead of the Company’s Special Meeting of
- PR20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth StrategyCEO Jonathan Cohen to Discuss Laboratory Franchise Model, 2027 Licensing Plans, Potential Acquisitions, FDA Strategy, and Firefighter Cancer Screening Initiatives Webinar to Be Held Wednesday, November 4, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 BioLabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, November 4, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, President and Chief Executive Officer o
- SECSEC Form DEFA14A filed by 20/20 Biolabs Inc.DEFA14A - 20/20 Biolabs, Inc. (0001139685) (Filer)
- SECSEC Form DEF 14A filed by 20/20 Biolabs Inc.DEF 14A - 20/20 Biolabs, Inc. (0001139685) (Filer)
- SECSEC Form PRE 14A filed by 20/20 Biolabs Inc.PRE 14A - 20/20 Biolabs, Inc. (0001139685) (Filer)
- PR20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) (the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Summit 2026, being held October 13 and 14, 2026 at the Hard Rock Hotel New York. The Summit’s healthcare program takes place Wednesday, October 14. Mr. Cohen and Mr. Bergman will hold one-on-one meeti
- PR20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise ModelPresident and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 BioLabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, October 7, 2026, at 12:00 p.m. Eastern time. Jonathan
- SEC20/20 Biolabs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
- SEC20/20 Biolabs Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
- SEC20/20 Biolabs Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
- PR20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial OpportunityCEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Aug. 28, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 BioLabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its previously announced investor webinar on Wednesday, September 2, 2026 has been
- PR20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial OpportunityCEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Aug. 26, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 BioLabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, September 2, 2026, at 12:00 p.m. E
- SECSEC Form DEFA14A filed by 20/20 Biolabs Inc.DEFA14A - 20/20 Biolabs, Inc. (0001139685) (Filer)
- SEC20/20 Biolabs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
- SECSEC Form 424B3 filed by 20/20 Biolabs Inc.424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)
- SECSEC Form 424B3 filed by 20/20 Biolabs Inc.424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)
- SEC20/20 Biolabs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
- PR20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly LevelBest Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5% Company Expands OneTest™ Across Firefighter, Occupational Health, Military, and Physician Practice Markets Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic d
- SEC20/20 Biolabs Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
- PR20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development TourChief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., July 30, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 BioLabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, August 5, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs, will discuss the Company’s rec
- PR20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up StrategyManagement Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and Chronic Diseases GAITHERSBURG, Md., July 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that members of its management team participated in BIO Asia-Taiwan July 15-19 and held strategic meetings in Taipei, Tokyo, and Seoul with companies, investors, laboratories, preventat
- PR20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred StockAgreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) (the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into a standstill agreement (the "Agreement") with Streeterville Capital, LLC ("Streeterville") relating to the Company’s outstanding Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The Agreement became effective on July 16, 2026. Under the terms of
- SEC20/20 Biolabs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
- PR20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue GrowthCompany Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection GAITHERSBURG, Md., July 09, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) (the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today highlighted key themes from its inaugural investor webinar held on July 1, 2026. The Company presented its strategy for advancing OneTest™ for Cancer toward potential Medicare reimbursement under the new statutory pathway for FDA-authorized multi-cancer early detection ("MCED") blood tests beginning in 202
- SEC20/20 Biolabs Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)
AIDX FAQ
8 questionsWhat is the latest news on AIDX?
In the last 30 days Quantisnow tracked 4 wire items for AIDX: 2 SEC filings and 2 press releases and news items. The most recent was published on November 5, 2026.What is AIDX revenue?
20/20 Biolabs Inc. (AIDX) reported $2.05M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 16.7% from the year before.Is AIDX profitable?
No. 20/20 Biolabs Inc. reported a net loss of $3.74M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does AIDX have?
20/20 Biolabs Inc. reported $4.55M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does AIDX stock trade?
20/20 Biolabs Inc. (AIDX) is listed on NASDAQ.What sector and industry is AIDX in?
20/20 Biolabs Inc. operates in the Health Care sector, Precision Instruments industry.What companies are similar to AIDX?
Notable peers in the same industry include ULS (UL Solutions Inc.), NEO (NeoGenomics Inc.). Compare AIDX side-by-side with any of them on Quantisnow.How can I track AIDX on Quantisnow?
Quantisnow aggregates 20/20 Biolabs Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AIDX to receive live email and push alerts on every new disclosure.